BARD1 and neoplasm: In addition, VEGFR2 inhibition in combination with talazoparib only modestly reduced tumor growth in the Brca1-def and Bard1-def models, whereas Flt1 inhibition in combination with talazoparib resulted in prominent tumor regression.